SEC Form 4 · accession 0001104659-26-101674
OCULAR THERAPEUTIX, INC · OCUL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Kaiser
Officer — Chief Development Officer
Period of report
Aug 24, 2026
Accepted (ET)
Aug 26, 2026 · 5:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001393434
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Aug 24, 2026 | S | 3,035 | $10.77 | D | 264,378 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6429 to $10.9125, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3Includes 1,272 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.